RxDoctor Payments Data

Trina Eagal

Family · Stockton, CANPI 1407203573

Payments from drug & device makers

$3,384in general payments, 2019–2025

Across 84 payments — averaging $40.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Abbott$750
  • Actelion Pharmaceuticals US, Inc.$308
  • Novartis$237
  • Merck$223
  • Pfizer$191
  • plus $638 from 13 others

What the payments were for

  • Food & beverage$3,28597%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,384 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$1,725
Medicare patients
21
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan92$77,624
FarxigaDapagliflozin Propanediol58$58,493
JardianceEmpagliflozin19$14,629
EliquisApixaban19$13,900
Bumetanide36$716
Potassium Chloride21$680
Metoprolol Succinate58$594
Spironolactone85$569
Torsemide27$540
Furosemide52$275
Amiodarone Hcl14$201
Carvedilol27$178
Atorvastatin Calcium11$148
Hydralazine Hcl29$112
Losartan Potassium11$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$237$77,62492 claims
AstraZenecaFarxiga$100$58,49358 claims
Boehringer IngelheimJardiance$30$14,62919 claims
PfizerEliquis$191$13,90019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →